Ask AI
ProCE Banner Activity

Endometrial Cancer Landscape: Experts Review Latest Clinical Data From SGO 2025

Clinical Thought

Read this commentary with our thoughts on new insights from SGO 2025 on factors contributing to ongoing disparities in care, available and emerging biomarkers, and clinical data informing the treatment landscape for patients with endometrial cancer.

Released: June 20, 2025

Expiration: December 19, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme LLC.

Eisai

GlaxoSmithKline

Merck Sharp & Dohme, LLC

Disclosure

Primary Author

Eloise Chapman-Davis, MD, FACOG, has no relevant financial relationships to disclose.

Whitney S. Graybill, MD, MS: consultant/advisor/speaker: Eisai, GSK.

Angeles Alvarez Secord, MD, MHSc: researcher: AbbVie, Aravive, AstraZeneca, Eisai, Ellipses Pharma, GlaxoSmithKline, I-Mab Biopharma, Karyopharm, Merck, Mersana, Myriad, OncoQuest/CanariaBio, Roche/Genentech, Seagen, VBL Therapeutics, Zentalis; consultant/advisor/speaker: AbbVie; individual publicly traded stock/stock options: Amgen, Johnson & Johnson.